Literature DB >> 26109736

Recommendations for the management of autoinflammatory diseases.

Nienke M ter Haar1, Marlen Oswald2, Jerold Jeyaratnam3, Jordi Anton4, Karyl S Barron5, Paul A Brogan6, Luca Cantarini7, Caroline Galeotti8, Gilles Grateau9, Veronique Hentgen10, Michael Hofer11, Tilmann Kallinich12, Isabelle Kone-Paut13, Helen J Lachmann14, Huri Ozdogan15, Seza Ozen16, Ricardo Russo17, Anna Simon18, Yosef Uziel19, Carine Wouters20, Brian M Feldman21, Sebastiaan J Vastert22, Nico M Wulffraat22, Susanne M Benseler23, Joost Frenkel3, Marco Gattorno24, Jasmin B Kuemmerle-Deschner2.   

Abstract

: Autoinflammatory diseases are characterised by fever and systemic inflammation, with potentially serious complications. Owing to the rarity of these diseases, evidence-based guidelines are lacking. In 2012, the European project Single Hub and Access point for paediatric Rheumatology in Europe (SHARE) was launched to optimise and disseminate regimens for the management of children and young adults with rheumatic diseases, facilitating the clinical practice of paediatricians and (paediatric) rheumatologists. One of the aims of SHARE was to provide evidence-based recommendations for the management of the autoinflammatory diseases cryopyrin-associated periodic syndromes (CAPS), tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) and mevalonate kinase deficiency (MKD). These recommendations were developed using the European League Against Rheumatism standard operating procedure. An expert committee of paediatric and adult rheumatologists was convened. Recommendations derived from the systematic literature review were evaluated by an online survey and subsequently discussed at a consensus meeting using Nominal Group Technique. Recommendations were accepted if more than 80% agreement was reached. In total, four overarching principles, 20 recommendations on therapy and 14 recommendations on monitoring were accepted with ≥80% agreement among the experts. Topics included (but were not limited to) validated disease activity scores, therapy and items to assess in monitoring of a patient. By developing these recommendations, we aim to optimise the management of patients with CAPS, TRAPS and MKD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Fever Syndromes; Multidisciplinary team-care; Treatment

Mesh:

Year:  2015        PMID: 26109736     DOI: 10.1136/annrheumdis-2015-207546

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  73 in total

1.  Autoinflammation. Management of hereditary recurrent fevers--SHARE experience.

Authors:  Guillaume Sarrabay; Isabelle Touitou
Journal:  Nat Rev Rheumatol       Date:  2015-08-18       Impact factor: 20.543

Review 2.  Autoinflammatory Diseases with Periodic Fevers.

Authors:  Erdal Sag; Yelda Bilginer; Seza Ozen
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 3.  Dermatologic Manifestations of Monogenic Autoinflammatory Diseases.

Authors:  Kyawt Win Shwin; Chyi-Chia Richard Lee; Raphaela Goldbach-Mansky
Journal:  Dermatol Clin       Date:  2017-01       Impact factor: 3.478

Review 4.  [Autoinflammatory syndromes : Practical approach to diagnostics and therapy].

Authors:  J B Kümmerle-Deschner
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

Review 5.  An Update on the Use of Immunomodulators in Primary Immunodeficiencies.

Authors:  Pandiarajan Vignesh; Amit Rawat; Surjit Singh
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

Review 6.  Efficacy and safety of anakinra in tumor necrosis factor receptor-associated periodic syndrome (TRAPS) complicated by severe renal failure: a report after long-term follow-up and review of the literature.

Authors:  Stefano Gentileschi; Donato Rigante; Antonio Vitale; Jurgen Sota; Bruno Frediani; Mauro Galeazzi; Luca Cantarini
Journal:  Clin Rheumatol       Date:  2017-05-23       Impact factor: 2.980

Review 7.  Review: Found in Translation: International Initiatives Pursuing Interleukin-1 Blockade for Treatment of Acute Kawasaki Disease.

Authors:  Jane C Burns; Isabelle Koné-Paut; Taco Kuijpers; Chisato Shimizu; Adriana Tremoulet; Moshe Arditi
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

Review 8.  Monogenic Periodic Fever Syndromes: Treatment Options for the Pediatric Patient.

Authors:  Seza Ozen; Selcan Demir
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

9.  Febrile infection-related epilepsy syndrome treated with anakinra.

Authors:  Daniel L Kenney-Jung; Annamaria Vezzani; Robert J Kahoud; Reghann G LaFrance-Corey; Mai-Lan Ho; Theresa Wampler Muskardin; Elaine C Wirrell; Charles L Howe; Eric T Payne
Journal:  Ann Neurol       Date:  2016-11-14       Impact factor: 10.422

Review 10.  Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature.

Authors:  Yanxia Chen; Xingqi Huang; Sujie Zheng; Zhongliang Zhu; Wei Yang; Jinlin Liu
Journal:  Clin Rheumatol       Date:  2018-02-15       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.